Moderna's mFlusiva Nears Historic FDA Decision on August 5 Amid Norovirus Vaccine Setback

Moderna's mFlusiva Nears Historic FDA Decision on August 5 Amid Norovirus Vaccine Setback

Moderna is preparing for an August 5, 2026, Prescription Drug User Fee Act (PDUFA) target action date for its investigational seasonal influenza vaccine, mFlusiva (mRNA-1010). If approved, mFlusiva would mark the world's first messenger RNA (mRNA) seasonal flu vaccine to receive regulatory clearance, establishing a landmark milestone for the mRNA platform.¹

The upcoming decision represents a critical financial and strategic catalyst for Moderna, which is facing a broader 2026 operating loss (exceeding $800 million per quarter) due to high pipeline spending and a recent clinical setback: on July 31, 2026, Moderna announced that its experimental norovirus vaccine (mRNA-1403) failed to meet its interim efficacy bar, requiring the Phase 3 trial to extend into a fourth season.

Unanimous Advisory Support and Clinical Background

The Biologics License Application (BLA) for mFlusiva is strongly backed by the FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC), which voted unanimously (9-0) on June 18, 2026, that the vaccine's benefits outweigh its risks for preventing influenza in adults aged 50 to 64 years and in adults aged 65 years or older.

The vaccine encodes surface hemagglutinin (HA) glycoproteins from four World Health Organization (WHO)-recommended seasonal influenza strains (A/H1N1, A/H3N2, B/Victoria, and B/Yamagata). In Phase 3 trials, mFlusiva demonstrated robust safety and superior immunogenicity compared to standard-of-care seasonal influenza vaccines.

Commercial Stakes and Risks

An approval on or before the August 5 deadline would give Moderna its fifth approved commercial product, allowing the company to roll out the vaccine in time for the 2026–2027 respiratory season. This would help rebuild Moderna's respiratory franchise and offset declining COVID-19 vaccine revenues.

If the FDA declines approval, the most likely adverse scenario would be a Complete Response Letter (CRL) requesting additional clinical data, particularly for the high-risk elderly cohort (65+). Moderna has indicated that in the event of a CRL, it remains committed to pursuing approval through supplementary clinical evaluations.